Search Results

The CG-6108 ACT-3L Continuous ECG Monitor and Arrhythmia Detector is intended for use by patients who experience transient symptoms that may suggest cardiac arthythmia. The device continuously monitors patient ECG, automatically generates an alert triggered by an arrhythmia detection algorithm, or generates an alert manually triggered by the patient, and transmits the recorded data trans-telephonically to a monitoring center provides the ECG data to the medical practitioner for evaluation.

The CG-6108 ACT-3L Continuous ECG Monitor and Arrhythmia Detector is intended to be prescribed for patients who have demonstrated a need for cardiac monitoring and are at low risk of developing life-threatening arrhythmias. Conditions where the system should not be used include patients likely to experience primary Ventricular Fibrillation or Ventricular Tachycardia and patients who have other co-morbid cardiovascular conditions where an arrhythmia could be potentially life threatening.

This device has not been tested for and it is not intended for pediatric use.

The CG-6108 ACT-3L Continuous ECG Monitor and Arrhythmia Detector is designed for self-testing by patients at home and for analysis by medical professionals at a remote Monitoring Center.

The chest-worn sensor is used for the acquisition, recording, and transmission of the ECG signal. The device is equipped with 4 electrodes on a harness and it houses a 3.6V AA battery, a Bluetooth transceiver and a patient alert buzzer.

The ECG signals are transmitted via Bluetooth to a handheld device with a proprietary interactive application, configured to process and transmit the ECG recordings. The handheld device is a mobile computing device with a display and a touch input such as a cell phone. It has sufficient memory and processing capability to run the proprietary application.

When an arrhythmia event is detected, the handheld device transmits the recorded ECG information automatically via cellular link, to the Monitoring Center for professional analysis. When cellular service is unavailable the patient has an option to transmit via a landline telephone.

The modification that led to this submission was the change from a mobile platform with a Windows-based OS to one with an Android-based OS.

The provided document is a 510(k) premarket notification for the LifeWatch Technologies CG-6108 ACT-3L Continuous ECG Monitor and Arrhythmia Detector with Software Version 6.1.17. While it asserts substantial equivalence to a predicate device, it does not contain a detailed study report with specific acceptance criteria and performance data for the device's arrhythmia detection capabilities. Instead, it refers to internal validation reports and conformance to standards.

Therefore, the following information is based on what can be extracted from the document, with many fields indicated as "Not provided" because the detailed study information is not present in this summary.

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance
The document does not provide a sample size for the test set used to evaluate the arrhythmia detection algorithm, nor does it specify the data provenance (e.g., country of origin, retrospective/prospective). It refers to an internal report "Testing of the ACT-3L algorithm, LifeWatch Technologies, VATR-0164" but does not detail its contents.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
This information is not provided in the 510(k) summary.

4. Adjudication Method for the Test Set
This information is not provided in the 510(k) summary.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
The document does not mention an MRMC comparative effectiveness study or any effect size of human readers improving with or without AI assistance. The focus is on the device's automatic detection capabilities and transmission to a monitoring center for professional analysis.

6. Standalone Performance
Yes, a standalone performance assessment of the algorithm was conducted. The document states:

"Testing of the ACT-3L algorithm, LifeWatch Technologies, VATR-0164" was performed and passed. This indicates that the algorithm's performance in detecting arrhythmias (Atrial Fibrillation, Tachycardia, Bradycardia, and Pause) was evaluated independent of human intervention.

7. Type of Ground Truth Used
The specific type of ground truth used for validating the arrhythmia detection algorithm is not explicitly stated in the summary. For ECG arrhythmia detection, common ground truths include expert consensus (manual review by cardiologists) on annotated ECG recordings or reference annotations from established databases. Given the nature of cardiac monitoring, it is highly likely that expert consensus on ECG segments served as the ground truth, but this is an inference, not a direct statement from the document.

8. Sample Size for the Training Set
The document does not provide information on the sample size for the training set used to develop or train the arrhythmia detection algorithm.

9. How the Ground Truth for the Training Set Was Established
This information is not provided in the 510(k) summary.

Ask a specific question about this device

The CG-6108 ACT-3L Continuous ECG Monitor and Arrhythmia Detector is intended for use by patients who experience transient symptoms that may suggest cardiac arrhythmia. The device continuously monitors patient ECG, automatically generates an alarm triggered by an arrhythmia detection algorithm, or generates an alarm manually triggered by the patient, and transmits the recorded data transtelephonically to a monitoring center. The monitoring center provides the ECG data to the medical practitioner for evaluation.

CG-6108 ACT-3L Continuous ECG Monitor and Arrhythmia Detector is designed for self-testing by patients at home and for analysis by medical professionals at a remote Monitoring Center.

The chest-worn sensor is used for the acquisition, recording, and transmission of the ECG signal. The device is equipped with 4 electrodes on a harness and it houses a 3.6V AA battery, a Bluetooth transceiver and a buzzer.

The ECG signals are transmitted via Bluetooth to a handheld device with a proprietary interactive application, configured to process and transmit the ECG recordings. The handheld device is a mobile computing device with a display and a touch input such as a cell-phone. It has sufficient memory and processing capability to run the proprietary application.

When an arrhythmia event is detected the handheld device transmits the recorded ECG information automatically via cellular link, to the Monitoring Center or professional analysis. When cellular service is unavailable the patient has an option to transmit via a landline telephone.

The provided text describes the CG-6108 ACT-3L Continuous ECG Monitor and Arrhythmia Detector, but it is a 510(k) Summary, not a detailed study report. Therefore, it does not contain the full details required to answer all aspects of your request comprehensively. Specifically, information regarding specific acceptance criteria values, reported device performance metrics against those criteria, detailed sample sizes for test and training sets, data provenance, expert qualifications, adjudication methods, MRMC study results (effect size), and training set ground truth establishment are largely absent or only broadly mentioned.

However, based on the information available, here's what can be extracted:

1. Table of Acceptance Criteria and Reported Device Performance:

The document broadly states that the device was subjected to "extensive verification / validation testing" and "designed to ensure that the device meet all of its functional and performance requirements and is fit for its intended use." It also mentions conformance with the "Class II Special Controls Guidance Document: Arrhythmia Detector and Alarm, October 28, 2003" and ANSI/AAMI/ISO EC57:1998 (R) 2008 for "Testing and Reporting Performance Results of Cardiac Rhythm and ST Segment Measurement Algorithms."

Unfortunately, specific numerical acceptance criteria (e.g., sensitivity, specificity thresholds for arrhythmia detection) and the device's reported performance against these criteria are NOT provided in this summary. The summary only lists general categories of performance validation.

2. Sample Size Used for the Test Set and Data Provenance:

The document mentions "Arrhythmia Detection Algorithm Performance Validation" as part of the testing. However, it does not specify the sample size used for this validation or the data provenance (e.g., country of origin, retrospective/prospective nature of the data).

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications:

This information is not provided in the 510(k) summary. It only states that the monitoring center provides ECG data to the medical practitioner for evaluation, implying professional review, but it doesn't detail the ground truth establishment for the validation study itself.

4. Adjudication Method for the Test Set:

This information is not provided in the 510(k) summary.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size:

The document does not mention a multi-reader multi-case (MRMC) comparative effectiveness study evaluating human reader improvement with AI assistance. The focus seems to be on the algorithm's standalone performance and the system's ability to transmit data to a monitoring center for professional analysis.

6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done:

Yes, a standalone performance evaluation of the algorithm was done. The document explicitly states: "Arrhythmia Detection Algorithm Performance Validation." This implies that the algorithm's ability to detect cardiac events (Atrial Fibrillation, Tachycardia, and Pause) was validated independently of a human interpreter at the point of detection, although human input at the monitoring center is part of the overall clinical workflow.

7. The Type of Ground Truth Used:

The document does not explicitly state the type of ground truth used for the algorithm validation. Given the nature of ECG monitoring and arrhythmia detection, it is highly probable that the ground truth would typically be established by expert consensus of cardiologists or electrophysiologists reviewing the ECG traces. However, this is an inference, not an explicit statement in the provided text.

8. The Sample Size for the Training Set:

The document does not provide any information regarding the sample size used for the training set of the arrhythmia detection algorithm.

9. How the Ground Truth for the Training Set Was Established:

The document does not provide any information regarding how the ground truth for the training set was established.

In summary, the provided 510(k) summary focuses on demonstrating substantial equivalence to a predicate device and outlines the general testing performed to meet regulatory guidance. It does not contain the detailed clinical study results and methodology typically found in a full clinical validation report.

Ask a specific question about this device